iVAPS vs. S/T Modes as Non-invasive Weaning Strategy in COPD Patients

Not Applicable

Completed

• Conditions: COPD Exacerbation
• Interventions: Device: Extubation to NIV

• Registration Number: NCT03222271
• Lead Sponsor: Assiut University

Brief Summary

Invasive mechanical ventilation (IMV) is associated with numerous complications. Hence, patients should be weaned from the ventilator as early as possible. A number of randomized controlled trials have addressed whether noninvasive ventilation (NIV) can facilitate weaning in patients failing spontaneous breathing trials (SBT)s. Compared to invasive weaning, NIV weaning strategy showed reduced mortality, greater weaning success, less ventilator-associated pneumonia, shorter length of ICU and hospital stay and less re-intubation rate.

Most of the previous studies used pressure support ventilation with fixed pressure support, but no studies published on hybrid NIV modes.

Intelligent Volume Assured Pressure Support (iVAPS) is a recent NIV mode, which achieves a target alveolar ventilation by adjusting pressure support and respiratory rate automatically. In iVAPS, the target is alveolar ventilation not the tidal volume, taking into account a predicted dead space . This new mode has been investigated in stable chronic obstructive pulmonary disease (COPD) patients with domiciliary NIV and it was comparable to pressure support ventilation (PSV) regarding improvement in oxygenation, carbon dioxide (CO2) wash and therapy compliance.

Yet, less numerous studies have been performed on this mode when used for acute respiratory failure. These studies found that i-VAPS was comparable to PSV as regards PaCO2 and pH improvements, minute volume, pressure support and respiratory rate. No published data so far about the role of i-VAPS as a weaning mode in mechanically ventilated patients. So, this study aims to investigate this new mode in comparison to the standard S/T mode in weaning COPD patients using NIV.

Detailed Description

Invasive mechanical ventilation (IMV) is associated with numerous complications. Hence, patients should be weaned from the ventilator as early as possible . Approximately 25% and (14-22) % of mechanically ventilated patients experience difficult and prolonged weaning respectively. A number of randomized controlled trials have addressed whether NIV can facilitate weaning in patients failing SBTs. The most recent systemic review included 16 trials -mainly COPD patients- found that patients weaned with NIV had reduced mortality, greater weaning success, less ventilator-associated pneumonia, shorter length of ICU and hospital stay and less reintubation rate.

Most of the previous studies used pressure support ventilation with fixed pressure support, but no studies published on hybrid NIV modes. Intelligent Volume Assured Pressure Support (iVAPS) is a recent NIV mode, which achieves a target alveolar volume by adjusting pressure and respiratory rate automatically. In iVAPS, the target is alveolar ventilation not the tidal volume. taking into account a predicted dead space. This new mode has been investigated in stable COPD patients with domiciliary NIV and it was comparable to pressure support ventilation (PSV) regarding improvement in oxygenation, CO2 wash and therapy compliance. Other studies focused on sleep quality and found that iVAPS was comparable to PSV regarding sleep quality, arousal, O2 de-saturation index, increase in therapy adherence and decrease in median PS needed with iVAPS.

Yet, less numerous studies have been performed on this mode when used for acute respiratory failure. These studies investigated the outcomes in acute hypercapnic respiratory failure and found that iVAPS was comparable to PSV as regards PaCO2 and logarithm of hydrogen ion concentration (pH) improvements, minute volume, pressure support and respiratory rate. No published data about the role of iVAPS as a weaning mode in mechanically ventilated patients.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study First Submitted: 2017-07-13
• Study First Submitted QC: 2017-07-17
• Study First Posted: 2017-07-19
• Study Start: 2017-10-25
• Primary Completion: 2020-09-30
• Study Completion: 2020-09-30
• Status Verified: 2021-01
• Last Update Submitted: 2021-01-11
• Last Update Posted: 2021-01-13

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 80

Inclusion Criteria

All patients in acute exacerbation of COPD who are mechanically ventilated will be included in this study.

Read More

Exclusion Criteria

• Age < 18 years or >75 years.
• Other chest diseases (pneumonia, bronchiectasis, pulmonary embolism, pulmonary fibrosis...).
• Tracheostomized patients.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
I) Extubation to NIV (S/T mode)	Extubation to NIV	The patients will receive NIV using S/T mode after extubation with the following parameters: * Expiratory Positive Airway Pressure (EPAP): 4-8 centimeter water (cmH2O). * Inspiratory Positive Airway Pressure (IPAP): 12-20 cmH2O. * Respiratory rate (RR): 10-12 breath/minute.
II) Extubation to NIV (iVAPS) mode	Extubation to NIV	The patients will receive NIV using iVAPS mode after extubation with the following parameters: * Patient's height in cm.. * Target alveolar ventilation (Va): adjusted provided that tidal volume is 8 ml/kg of ideal body weight (IBW). * Expiratory Positive Airway Pressure (EPAP) :4-8 cmH2O * Minimum and maximum Pressure Support (PS) :8-16 * Respiratory rate :10-12 breath/min.

Primary Outcome Measures

Name	Time	Method
Success rate of either modes.	48 hours	-Success is considered when the patient is able to achieve the following: pH \>7.35,decrease in partial pressure of carbon dioxide (PaCO2) of \>15-20%, partial pressure of oxygen (PaO2)\>60 mmHg, arterial oxygen saturation (SaO2)\> 90% on fraction of inspired oxygen (FiO2) \<40%, RR \< 24 bpm and no signs of respiratory distress like agitation, diaphoresis or anxiety.; Numbers of successful cases is recorded

Secondary Outcome Measures

Name	Time	Method
Length of ICU stay	An average of 30 days	Measured in days
Re-intubation rate in each group.	30 days	Measured by number of the patients re-intubated in each arm
Duration spent on NIV	An average of 30 days	Measured in days
Mortality rate in each group	30 days	Measured by number of the patients re-intubated in each arm
Degree of patient's comfort	An average of 30 days	A specific questionnaire (pain in the forehead, nose, cheeks, and chin, air leak at eyes and mouth, dry nose and mouth, skin inflammation and claustrophobia. The patients answers to each question (sore0-3 in terms of intensity). The total score is calculated by adding the individual scores of each item mentioned above.

Trial Locations

Locations (2)

Assiut University Hospital; 🇪🇬 Assiut, Egypt

Assiut University Hospital - RICU; 🇪🇬 Assiut, Egypt